We carefully read the paper by Zimmerman and colleagues 1 about the possible effect of hydroxyurea on the transcranial doppler flow velocities in children with sickle cell disease. We reviewed the transcranial dopplers (TCD) performed on the children with sickle cell disease in our hospital from 0 to 25 years old, treated or not treated with hydroxyurea, and we compared the trend of the time-averaged maximum velocity (TAMV) measured in the middle cerebral arteries and the incidence of stroke.Among our 119 patients, we found that in the patients not treated with hydroxyurea, the velocity increased with age to a maximum between 6 and 9 years old (P Ͻ .05). This significant increase does not appear in the patients treated with hydroxyurea ( Figure 1). Following the 85 patients who had repeated TCD after a mean duration of 3.1 (Ϯ 1.5) years, we noticed that the velocity was increasing in the patients whose first TCD was normal (148 Ϯ 16 cm/s to 172 Ϯ 21 cm/s, n ϭ 34, P Ͻ .01), stabilizing in the patients whose first TCD was conditional (181 Ϯ 8 cm/s to 181 Ϯ 25 cm/s, n ϭ 30, P ϭ .75); and decreasing in the patients whose first TCD was abnormal and who were thereafter treated by hydroxyurea between the first and the second TCD (235 Ϯ 18 cm/s to 202 Ϯ 34 cm/s, n ϭ 21, P Ͻ .01). In these 21 patients with an abnormal first TCD, the velocities decreased to the normal/conditional range in 8 of them. This strengthens the observation of Zimmerman and colleagues 1 that children with the highest baseline doppler velocity had the greatest decrease in response to hydroxyurea.In the 80 patients treated with hydroxyurea with a follow-up of 555 patient-years, 2 presented stroke, and of the 4 patients with a previous history of stroke, only one presented a new episode for a follow-up of 35 patient-years. For the 23 patients receiving hydroxyurea based on an abnormal TCD and no other clinical risk, no stroke was recorded for 84 patient-years. Seventeen of these 23 patients (mean age 5.5 Ϯ 1.8 years) had repeated TCD after a mean duration of hydroxyurea treatment of 31 (Ϯ 14) months. Their mean velocity dropped from 231 (Ϯ 22) cm/s to 208 (Ϯ 24) cm/s (P Ͻ .01). Magnetic resonance angiography (MRA) from 14 of these patients showed vascular stenosis in 6 of them. This stenosis persisted in 2 of the 5 patients on repeated MRA performed after a mean time of 4 (Ϯ 1) years.Concerning the secondary prevention of stroke, the recurrence rate of stroke in our patients treated with hydroxyurea was 2.9 for 100 patient-years, similar to that recorded in chronically transfused patients. 2,3 However, in the primary prevention of stroke, the incidence of first stroke in our patients with hydroxyurea was 0.36 for 100 patient-years, lower than in nontransfused patients of other larger cohorts 4 and lower than in the cohort of Zimmerman and colleagues (0.52 for 100 patient-years), 1 without using maximum tolerated dose of hydroxyurea. 5 Our preliminary results therefore indicate that, in the patients at risk for stroke on the basis of transcranial do...

Clinical control of disease activity by etanercept in MTX-refractory polyJIA is associated with rapidly instituted catch-up growth and improvement of bone mineralization and body composition. In recently diagnosed polyJIA patients treated with MTX the relation between clinical response and these parameters was less evident. Preliminary data on serum IL-6 and osteoprotegerin levels indicate that the beneficial effects seen with etanercept therapy may be related to its control of systemic IL-6 production and enhancement of osteoblast activity.

This study suggests that pica remains an unknown and under-reported clinical problem in children with SCD and seems to be related to the severity of anemia. The next step of this project aims to clarify causal mechanisms for pica and its association with SCD in a larger population.